
PD-L1 and TMB as biomarkers in the IMvigor211 trial of atezolizumab vs. chemo for bladder cancer
Thomas Powles

Severity of immune checkpoint inhibitors' side effects
Jean Klastersky

The LUME BioNIS trial: an exploratory study into lung cancer biomarkers
Martin Reck

Adjuvant chemotherapy for breast cancer: who needs it?
Fatima Cardoso

Topics highlighted at a chaired discussion on treatment and supportive care
Catherine Oakley